Pink Sheet is part of the Business Intelligence Division of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By


Pfizer Launch Plans For Lyrica Fibromyalgia Approval Include Patient Groups

Executive Summary

Pfizer's first steps in marketing Lyrica's new indication for fibromyalgia - the first FDA approval for the condition - will be partnering with patient advocacy groups to raise awareness and conduct educational programs

Related Content

Cymbalta Fibromyalgia Approval Sets Another REMS Precedent
Pfizer Matches Lilly In Grant Spending For 1st Quarter; Fibromyalgia Is Focus
Pfizer Faces $2 Billion Generic Drag On Revenues In 2008
AstraZeneca Aims To Grow Seroquel XR With Added Indications, Not Switches
Cymbalta fibromyalgia indication
Lyrica DTC For Fibromyalgia “Consistent” With PhRMA Guidelines – Pfizer
Pfizer’s U.S. Overhaul Is Paying Off, But Work Is Not Done – CEO Kindler
Lyrica price (correction)
Nebivolol Education Efforts Will Tout Performance In Hypertension Subgroups
Pfizer Lyrica Launch Awaits Controlled Substance Scheduling



Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts